If you suffered losses exceeding $100,000 in Regeneron between November 2, 2023 and October 30, 2024 and would like to ...
Regeneron Pharmaceuticals Inc. closed 42.77% short of its 52-week high of $1,211.20, which the company achieved on August ...
Regeneron Pharmaceuticals Inc.'s executives and board members overstated its key eye treatment’s average selling price, ...
A federal judge in Massachusetts reached the same heightened causation standard as applied in the court's 2023 decision in ...
General Douglas MacArthur High School senior Melody Hong has been named one of 300 semifinalists in the 2025 Regeneron ...
With a market cap of $77.3 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company dedicated to ...
The Fortune 500 pharma giant will sequence the exomes of 10 million people, with the goal of developing new therapies and ...
Failed to fetch dynamically imported module: https://nz.finance.yahoo.com/assets/_app/immutable/nodes/98.YCWzV16B.js ...
UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to "Neutral" from "Buy" given uncertainty around its key Eylea franchise. Brokerage slashed price target to $738 from $1130.
Buying $100 In REGN: If an investor had bought $100 of REGN stock 15 years ago, it would be worth $2,688.18 today based on a ...
UBS downgraded Regeneron (REGN) to Neutral from Buy with a price target of $738, down from $1,130. The firm believes there is a disconnect ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback